Isabel has returned to the group following a three month internship at Alkermes Biopharmaceutical. During the internship Isabel worked as part of the R&D Formulations department, developing formulations for new oral dose drug substances, which allowed her to get experience in early stage formulation development through to scale-up, as well as investigating the potential for PAT (Process Analytical Technology), in the form of various spectroscopic techniques, with a view to inline process monitoring. This opportunity was made possible due to a collaboration with Tarek Zeidan (Alkermes, Waltham) on Isabel’s PhD project over the last three years. This experience will greatly benefit Isabel as well as the wider Gunnlaugsson group.
Örn Almarsson, Head of Formulation of Moderna Therapeutics in Cambridge, Massachusetts, gave a lecture about his work titled “Messenger RNA: A Novel Therapeutic Approach”, today. Moderna Therapeutics have demonstrated the possibilities offered by mRNA-based treatments, establishing partnerships with Merck, receiving awards for their research achievements and raising over $1.1 billion in equity financing.
Örn was invited to speak to TBSI by Thorri, of whom he is a longtime friend. It was a pleasure to have him talk about his work and provide a unique insight into the world of cutting-edge industry research.
Thorri introduces Orn’s Work
Orn answers questions from the audience
The TG Group had a very productive meeting with a delegation of scientists from biopharmaceutical company Alkermes. A lot of fascinating discussion and knowledge exchange went on over the course of the afternoon and there was even time to visit the Book of Kells in Trinity’s Old Library. Students and postdoctoral researchers presented their work and fruitful discussion about the limitations and applications of various projects followed.